ESG414

ESG414 is an investigational antibody-drug conjugate (ADC) being developed by Shanghai Escugen Biotechnology. The drug is designed to target an undisclosed antigen, utilizing the precision of a monoclonal antibody to deliver a cytotoxic payload directly to cells expressing the target. While the specific molecular target and primary clinical indications remain confidential according to the developer's pipeline, ESG414 is part of a robust portfolio of ADC candidates aimed at treating various malignancies. The platform typically involves a linker technology that ensures the stability of the conjugate in systemic circulation while allowing for the efficient release of the payload upon internalization into the target cell.